## Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208(b)(3)

Christy Sanborg, M.D.

**Committee**: Arthritis Drugs Advisory Committee

Meeting Date: November 29, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the committee's discussions of the safety and efficacy of New Drug Application NDA 20-998, supplement 021, trade name, Celebrex (celecoxib), a non-steroidal anti-inflammatory drug (COX-2 inhibitor), manufactured by Searle Ltd. for G.D. Searle LLC, subsidiaries of Pfizer, for the proposed indication of the relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) in patients two years and older. I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

<b>Type of Interest</b>	Nature	Magnitude				
Spouse's Unrelated Consulting	Competing Firm	Less than \$10,001 per year				
I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.						
/S/ Signature of SGE		October 24, 2006 Date				